AI-based COVID screening tools prove useful in emergency, admitting departments

Oxford researchers have developed and prospectively validated two AI tools that can quickly screen hospital patients for COVID-19 using routine clinical data.

They designed one tool for use in inpatient admitting and another for the ED. Both tools leverage health data that’s usually available within an hour of the patient’s arrival at either department.  

Andrew Soltan, MB BChir, and colleagues describe their work in a study running in The Lancet Digital Health.

“Our ED and admissions models effectively identified patients with COVID-19 among all patients presenting and admitted to hospital,” the authors write. “On validation, using prospective cohorts of all patients presenting or admitted to the Oxford University Hospitals, our models achieved high accuracies and [high] negative predictive values compared with PCR test results.”

The latter has limited sensitivity for ruling out COVID, the authors note, and can take up to 72 hours to produce results.

Soltan and co-authors suggest their algorithms be considered for wide deployment not only to rule out COVID but also to assist with care decisions, guide safe patient transport and serve as a pretest for diagnostic molecular testing.

The study is available in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.